Table 6 SRF and HRF changes in subjects with different stages of DME after anti-VEGF treatment.
Parameters Median (IQR) | Early DME (n = 37) | Advanced DME (n = 35) | Severe DME (n = 36) | Atrophic DME (n = 18) | P-value |
|---|---|---|---|---|---|
Baseline SRF, n(%) | 0.004 | ||||
Present | 3(8.11) | 14(40) | 14(38.89) | 3(16.67) | |
Absent | 34(91.89) | 21(60) | 22(61.11) | 15(83.33) | |
SRF after treatment, n(%) | 0.015 | ||||
Present | 2(5.41) | 5(14.29) | 12(33.33) | 3(16.67) | |
Absent | 35(94.59) | 30(85.71) | 24(66.67) | 15(83.33) | |
P-value | 1.0 | 0.030 | 0.806 | 1.0 | |
Baseline HRF, n (%) | 0.018 | ||||
≥ 30 | 6(16.22) | 16(45.71) | 17(47.22) | 8(44.44) | |
< 30 | 31(83.78) | 19(54.29) | 19(52.78) | 10(55.56) | |
HRF after treatment, n (%) | 0.033 | ||||
≥ 30 | 5(13.51) | 7(20) | 15(41.67) | 6(33.33) | |
< 30 | 32(86.49) | 28(80) | 21(58.33) | 12(66.67) | |
P-value | 1.0 | 0.041 | 0.813 | 0.733 | |
